Code to Cure: Digital Therapeutics and the Future of Pharma (Paperback) (ISBN-13: 9789347311147)

When medicine is written in code, how do you market the cure?

A quiet revolution is reshaping healthcare. From video games prescribed for ADHD to AI-powered platforms preventing diabetes, digital therapeutics (DTx) are no longer experiments-they are becoming medicine itself. And with this shift comes an urgent question for pharma: how do we market therapies made not of molecules, but of algorithms?

In Code to Cure: Digital Therapeutics and the Future of Pharma, Subba Rao Chaganti-a renowned author and thought leader in pharmaceutical marketing-offers the first comprehensive guide to understanding and leveraging digital therapeutics in the pharma landscape.

Blending rigorous research with real-world case studies, the book takes you inside the fast-evolving world of Dtx:

- What digital therapeutics are - and how they differ from wellness apps.

- Why regulators like the FDA, EMA, and Germany's DiGA are setting new global benchmarks.

- How pharmaceutical companies can align digital therapeutics (DTx) with brand strategy, payer demands, and patient needs.

- Case studies of pioneers like Pear Therapeutics, Akili Interactive, Propeller Health, Omada, and Kaia Health.

- The role of AI, wearables, and telemedicine in scaling digital care.

- Strategic frameworks for commercialization, adoption, and measuring success.

Whether you are a brand manager, marketer, student, or healthcare innovator, this book will help you navigate the opportunities and challenges of a world where medicine is not just prescribed, but downloaded.

Engaging, insightful, and practical, Code to Cure is not just about the future of pharma marketing; it is about the future of healthcare itself.